Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Pancreatic cancer is almost invariably associated with mutations in the KRAS gene, most commonly KRASG12D, that result in a dominant-active form of the KRAS GTPase. However, how KRAS mutations promote pancreatic carcinogenesis is not fully understood, and whether oncogenic KRAS is required for the maintenance of pancreatic cancer has not been established. To address these questions, we generated two mouse models of pancreatic tumorigenesis: mice transgenic for inducible KrasG12D, which allows for inducible, pancreas-specific, and reversible expression of the oncogenic KrasG12D, with or without inactivation of one allele of the tumor suppressor gene p53. Here, we report that, early in tumorigenesis, induction of oncogenic KrasG12D reversibly altered normal epithelial differentiation following tissue damage, leading to precancerous lesions. Inactivation of KrasG12D in established precursor lesions and during progression to cancer led to regression of the lesions, indicating that KrasG12D was required for tumor cell survival. Strikingly, during all stages of carcinogenesis, KrasG12D upregulated Hedgehog signaling, inflammatory pathways, and several pathways known to mediate paracrine interactions between epithelial cells and their surrounding microenvironment, thus promoting formation and maintenance of the fibroinflammatory stroma that plays a pivotal role in pancreatic cancer. Our data establish that epithelial KrasG12D influences multiple cell types to drive pancreatic tumorigenesis and is essential for tumor maintenance. They also strongly support the notion that inhibiting KrasG12D, or its downstream effectors, could provide a new approach for the treatment of pancreatic cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prior studies have demonstrated that genetic ablation of KRAS expression leads to cell cycle arrest and death in cell lines and potent tumor regressions in animal models of PDAC (5–7).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [7]
In the citing paper
“Extinguishing the expression of mutant Kras in the pancreas led to rapid tumor regression, thus demonstrating a critical role of Kras in tumor maintenance (73, 78).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [78]
In the citing paper
“Withdrawal of oncogenic Kras resulted in regression of invasive neoplasia, including regression of metastatic disease63–65.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [63]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Research works printed but not linked: 2
- Klimstra, 1994, Am J Pathol., 145, 1547
- Caldwell, Oncogene.
Cited by
Items 701–769 of 769
Perspective on the Immunotherapy of Pancreatic Cancer
Keenan, B. P., & Tempero, M. A. (2021) · Cancer immunotherapy · doi:10.1007/13905_2021_9
Mutant K-Ras Mediated Oxidative Stress in Pancreatic Cancer
Thomas, D., Sagar, S., Caffrey, T., & Radhakrishnan, P. (2021) · Springer eBooks · doi:10.1007/978-981-15-4501-6_94-1
Tumour mutations in long noncoding RNAs enhance cell fitnessPreprint
Esposito, R., Lanzós, A., Polidori, T., Guillen-Ramirez, H., Merlin, B. M., Mela, L., Zoni, E., Büchi, I., Hovhannisyan, L., McCluggage, F., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.06.467555 · Cited by 1
Occurrence of Malignant Neoplasms
Shimizu, K. (2014) · Springer eBooks · doi:10.1007/978-3-642-55086-7_26
Klein, L. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8402
Ductal Adenocarcinoma and Variants
Karamitopoulou, E. (2022) · Encyclopedia of pathology · doi:10.1007/978-3-319-28845-1_5538-1
Finding Method in the Madness of Pancreatic Carcinogenesis
Sherman, M. H. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.03.004
Role of enhancer activation in pancreatic cancer metastasis
Cejas, P., Mendiola, M., & Feliú, J. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.04.02
Precision Medicine in Pancreatic Cancer
Beech, J. (2015) · doi:10.18130/v3hp0v
Tsokos, G. C. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727394204.793570386
Leslie, N. R., & Porcza, L. M. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737998700.793575573
PKC-alpha promotes phosphorylation of KRAS suppressing its oncogenic propertiesPreprint
Joglekar, T., Ku, A., Schollaert, E., Gong, Y., Stewart-Ornstein, J., Urisman, A., & Wang, M.-T. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.24.493257 · Cited by 1
“A mouse pancreatic adenocarcinoma cell line (iKRAS*), which maintains both wild-type KRAS alleles without doxycycline induction [32, 33], were insensitive to prostratin (Fig.”
BackgroundMethodMasugi, Y., Takamatsu, M., Tanaka, M. H., Hara, K., Inoue, Y., Hamada, T., Suzuki, T., Arita, J., Hirose, Y., Kawaguchi, Y., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4197932
Consortium bibliometric analysis of hotspots and frontiers of immunotherapy in pancreatic cancerPreprint
Xu, Q., Zhou, Y., Zhang, H., Li, H., Qin, H., & Wang, H. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.10.515943
Targeted Cancer Therapy: KRAS-Specific Treatments for Pancreatic Cancer
Choudhary, H., & Xodo, L. E. (2022) · Springer eBooks · doi:10.1007/978-981-16-1313-5_69-1
Experimental Model for Pancreatic Cancer and Its Therapeutic Implications in Clinical Research
Jayaraman, S., Ponnusamy, B., Rajagopal, P., Kumar, S. G., & Chandrasekar, K. (2022) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-1282-5_39-1
Management of Locally Advanced/Metastatic Disease: Medical Oncology
Mizrahi, J. D., & Wolff, R. A. (2022) · Springer eBooks · doi:10.1007/978-3-031-05724-3_9
Nanocarriers-Based Targeted Therapies for Pancreatic Cancer and Challenges Ahead
Sahoo, A., Alam, K., Daniel, S., Beg, S., Kumar, V., Hafeez, A., Rahman, M., & Almalki, W. H. (2022) · Springer eBooks · doi:10.1007/978-981-19-5558-7_7
Data from mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer
Driscoll, D. R., Karim, S. A., Sano, M., Gay, D. M., Jacob, W., Yu, J. Q., Mizukami, Y., Gopinathan, A., Jodrell, D. I., Evans, T. R. J., et al. (2023) · doi:10.1158/0008-5472.c.6508418.v1
Supplementary Methods from Canonical Wnt Signaling Is Required for Pancreatic Carcinogenesis
Zhang, Y., Morris, J. P., Yan, W., Schofield, H. K., Gurney, A. L., Simeone, D. M., Millar, S. E., Hoey, T. C., Hebrok, M., & di Magliano, M. P. (2023) · doi:10.1158/0008-5472.22394940
Self-citationZhang, Y., Yan, W., Collins, M. A., Bednar, F., Rakshit, S., Zetter, B. R., Stanger, B. Z., Chung, I., Rhim, A. D., & di Magliano, M. P. (2023) · doi:10.1158/0008-5472.22396185
Self-citationZhang, Y., Yan, W., Collins, M. A., Bednar, F., Rakshit, S., Zetter, B. R., Stanger, B. Z., Chung, I., Rhim, A. D., & di Magliano, M. P. (2023) · doi:10.1158/0008-5472.22396185.v1
Self-citationSupplementary Methods from Canonical Wnt Signaling Is Required for Pancreatic Carcinogenesis
Zhang, Y., Morris, J. P., Yan, W., Schofield, H. K., Gurney, A. L., Simeone, D. M., Millar, S. E., Hoey, T. C., Hebrok, M., & di Magliano, M. P. (2023) · doi:10.1158/0008-5472.22394940.v1
Self-citationData from CD4+ T Lymphocyte Ablation Prevents Pancreatic Carcinogenesis in Mice
Zhang, Y., Yan, W., Mathew, E., Bednar, F., Wan, S., Collins, M. A., Evans, R. A., Welling, T. H., Vonderheide, R. H., & di Magliano, M. P. (2023) · doi:10.1158/2326-6066.c.6548512.v1
Self-citationData from Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance
Ajina, R., Malchiodi, Z. X., Fitzgerald, A. A., Zuo, A., Wang, S., Moussa, M., Cooper, C. J., Shen, Y. G., Johnson, Q. R., Parks, J. M., et al. (2023) · doi:10.1158/2326-6066.c.6550273.v1
Yang, S., Imamura, Y., Jenkins, R. W., Cañadas, I., Kitajima, S., Aref, A. R., Brannon, A., Oki, E., Castoreno, A. B., Zhu, Z., et al. (2023) · doi:10.1158/2326-6066.22537418
Mehra, S., Garrido, V. T., Dosch, A. R., Lamichhane, P., Srinivasan, S., Singh, S. P., Zhou, Z., Silva, I. D. C., Joshi, C. G., Ban, Y. J., et al. (2023) · doi:10.1158/2767-9764.c.6708893
Targeted Cancer Therapy: KRAS-Specific Treatments for Pancreatic Cancer
Choudhary, H., & Xodo, L. E. (2023) · Springer eBooks · doi:10.1007/978-981-19-9776-1_69
Calligraphy tool offers clues to the origin of pancreatic cancer
Bednar, F., & di Magliano, M. P. (2023) · Nature · doi:10.1038/d41586-023-02518-4
Self-citationSelective epithelial expression of KRAS G12D mutation drives ductal pancreatic neoplasia in OncopigsPreprint
Jara, C. P., Al-Gahmi, A.-M., Lazenby, A. J., Hollingsworth, M. A., & Carlson, M. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.01.578513
Additional file 2 of Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells
Du, R., Sullivan, D. K., Azizian, N. G., Liu, Y., & Li, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14175865
KRAS-driven cancer models for in vivo pharmacology and drug discovery
Chugh, S., Dow, L. E., Singh, M., & Aguirre, A. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00004-8
Quémerais, C., Jean, C., Brunel, A., Decaup, E., Labrousse, G., Audureau, H., Raffenne, J., Belhabib, I., Cros, J. F., Perraud, A., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5064330
PP2A activation drives aberrant macropinocytosis and cell death in pancreatic ductal adenocarcinomaPreprint
Baral, G., Pfeffer, C. M., Filippelli, S. N., Doraivel, I., Heil, B. N., Gartenhaus, L. E., Hansen, K., Wu, J., Narla, G., Doud, E. H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.14.664742
Opsahl, E. L. L., & di Magliano, M. P. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0878
Prise en charge du cancer pulmonaire non à petites cellules avec mutation de KRAS
Chour, A., Lafitte, C., Boussageon, M., Pierret, T., & Duruisseaux, M. (2025) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(25)00078-3 · Cited by 2
ADAM17-dependent Autocrine and Paracrine Signaling Promotes Pancreatic Premalignant Progression
Wen, H.-J., Davis, E. T., Moore, J. S., Brender, S. M., Benitz, S., Wombwell, A. M., Loveless, I. M., Long, D. W., Salas-Escabillas, D. J., Lee, J., et al. (2025) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2025.101711
“This phenomenon was reminiscent of the findings with MEK inhibitors 12 or extinguishing Kras G12D expression entirely, 50 despite it being a target upstream of KRAS signaling.”
Additional file 1 of Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells
Du, R., Sullivan, D. K., Azizian, N. G., Liu, Y., & Li, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14175862
Sozzi, S., Manni, I., Ercolani, C., Diodoro, M. G., Bartolazzi, A., Spallotta, F., Piaggio, G., Monteonofrio, L., Soddu, S., Rinaldo, C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.27129495
Mathison, A., Kerketta, R., de Assuncao, T. M., Leverence, E. N., Zeighami, A., Urrutia, G., Stodola, T. J., di Magliano, M. P., Iovanna, J., Zimmermann, M. T., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16815929
Mathison, A., Kerketta, R., de Assuncao, T. M., Leverence, E. N., Zeighami, A., Urrutia, G., Stodola, T. J., di Magliano, M. P., Iovanna, J., Zimmermann, M. T., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16815935
Tian, L., Han, Q., Qiao, Y., Chu, P., & Chen, L. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02703
Etude de la reprogrammation métabolique de l' adénocarcinome canalaire pancréatique
Olivares, O. (2015) · theses.fr (ABES) · doi:10.70675/ef2c6a2czab6dz4a68z8004z1ade8605dadc
Carmona, S. (2017) · theses.fr (ABES) · doi:10.70675/f95cdb23zecb6z4543z9164ze58fd37f2268
Conséquences traductionnelles de la perte de 4E-BP1 dans l'adénocarcinome pancréatique
Müller, D. (2016) · theses.fr (ABES) · doi:10.70675/1f894fb2zc2daz446fza7f2z2b28408eb6e2
Analyse 3D des remodelages des réseaux neuronaux dans le cancer du pancréas
Lucchesi, A. (2018) · theses.fr (ABES) · doi:10.70675/ad846fa9z6d83z4bf4zb496zd84ac76097ad
Effet du TGFβ produit par le microenvironnement sur les tumeurs du pancréas exocrine
Cardot‐Ruffino, V. (2019) · theses.fr (ABES) · doi:10.70675/5a044019zf697z4071z9643zee4c85ba364f
Reyes, J. (2026) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · doi:10.5281/zenodo.18892592
Role of the stromal microenvironment in PDAC and resistance to therapies
Ode, A. (2024) · theses.fr (ABES) · doi:10.70675/0452e0e9z98e8z47d9za007zd4b472926aab
MicroRNA-based strategies to overcome the immunotherapy barrier in pancreatic ductal adenocarcinoma
徐慧文, Wang, Q., Cao, R., Qiu, Z., Liu, Y., Hu, J., Zheng, G., & Cheng, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1744566
“The PDAC TME is largely composed of CD45 + bone marrow – derived immune cells, particularly myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) (106, 107).”
Understanding development and cellular plasticity in the pancreas in health and disease
Torres-Cano, A., & Spagnoli, F. M. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01211-x · Cited by 2
“Moreover, multiple mesenchymal signals, essential for the expansion of early pancreatic progenitors and their subsequent differentiation, have been identified and many of these cues have conserved roles in humans 180–183 .”
Umemoto, K., Nakahara, K., Ohike, N., Satta, Y., Akihiro, S., Igarashi, Y., Nagata, Y., Kubota, Y., Takeda, H., Horie, Y., et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02447-9 · Cited by 1
“Among these, KRAS mutations are the primary drivers in pancreatic cancer, representing a genetic abnormality found in over 90% of invasive ductal pancreatic cancers [3, 4].”
LaRue-Nolan, K. C., Flores, L. F., Vera, R. E., Sigafoos, A. N., Hilario-Garcia, L., Almada, L. L., Tader, B. R., Rodriguez-Quevedo, M. F., May, D. G., Marks, D. L., et al. (2026) · Molecular and Cellular Biology · doi:10.1080/10985549.2026.2670710
Öz, H., & Canacankatan, N. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100440
Oncohistone inhibition reshapes tumor–microenvironment communication in Diffuse Midline Glioma (DMG)Preprint
Khairkhah, N., Ibrahim, M. M. H., Galban, S. L., Faunce, M., Rober, L., baker, C., Doherty, R., Cartaxo, R., Koschmann, C., Zhao, Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.17.731637
Hruban, R. H., & Kern, S. E. (2026) · Modern Pathology · doi:10.1016/j.modpat.2026.101059
KRAS mutations take different trajectories to drive pancreatic transformation
LaRue-Nolan, K. C., & Fernández-Zapico, M. E. (2026) · Developmental Cell · doi:10.1016/j.devcel.2026.07.013 · Cited by 1
Jeon, E., Song, J., & Sim, T. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2719780
Luchini, C. (2026) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-026-04681-1 · Cited by 1
Mariano, M. P., Sgarilli, E., Mijnlieff, D., Visuvasam, B., Blesio, A., Digiacomo, G., Cavazzoni, A., Ferracin, M., & Giovannetti, E. (2026) · Cancer Drug Resistance · doi:10.20517/cdr.2026.52 · Cited by 1
Mechanisms of Immune Cell Dysregulation in Pancreatic Ductal Adenocarcinoma
Ahmady, F., Luwor, R. B., & Kannourakis, G. (2026) · Biology · doi:10.3390/biology15181599 · Cited by 1
“Transgenic mice were used to induce and de-induce mutant KRAS with doxycycline [175,176].”
Advances in KRAS-Targeted Therapies for Pancreatic Cancer
Peshin, S., Zahid, A., Takrori, E., Hamedi, Z., & Rahman, S. (2026) · Cancers · doi:10.3390/cancers18182961
“This mutant KRAS is not only involved in tumor initiation, but also helps maintain tumor proliferation [12], which further adds to its importance as a potential target for the treatment of pancreatic cancer.”
Acinar‐Derived Organoids Reveal Stage‐Specific Control of Acinar Plasticity
Hou, Y., Li, S., Li, C., Lin, Z., He, D., Yang, L., Fu, L., Zhang, Q., Zhou, T., Yao, Y., et al. (2026) · Advanced Science · doi:10.1002/advs.78350
MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer
Rajesh, C., Sagar, S., Huang, Y., Mundry, C. S., Chaitankar, V., Shah, O. S., Sumeet, C., Caffrey, T., O’Connell, K. A., Swanson, B., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218927
Zhang, Y., Tang, S., Zhang, Y., Liu, J., Shi, X., Li, Y., Li, Y., Wang, H., Zhong, C., Sun, M., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.10.003 · Cited by 2
Self-citationMouse Models of RAS-Induced Tumors and Developmental Disorders
Guerra, C. E., & Barbacid, M. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1806-1_10
Metadata
- Authors
- Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M.
- Affiliations
- University of Michigan (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2012-02-01
- Volume
- 122
- Issue
- 2
- Pages
- 639-653
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3266788
- OpenAlex
- W2018159884
- Cited by
- 770
- References
- 66
- Citations by year
- 2026: 40 · 2025: 41 · 2024: 53 · 2023: 63 · 2022: 71 · 2021: 80 · 2020: 51 · 2019: 43 · 2018: 54 · 2017: 69 · 2016: 56 · 2015: 45 · 2014: 52 · 2013: 41 · 2012: 11
- FWCI
- 23.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association for Cancer Research
- Pancreatic Cancer Action Network
- American College of Surgeons
- Vanderbilt University
- University of Pennsylvania
- University of Michigan
- National Institutes of Health (NIH T32, P30 DK, 5-T32-HD007515)
- National Cancer Institute (R01CA151588, P50CA130810, P50CA13810)
- National Institute of General Medical Sciences (T32GM07315, T32GM007315)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034933)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (5-T32-HD007515, T32HD007505)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic cancer, KRAS G12D, oncogenic KRAS, pancreatic carcinogenesis, tumor maintenance, p53, precancerous lesions, epithelial differentiation, Hedgehog signaling, inflammation, tumor microenvironment, tumor regression, KRAS inhibition
- MeSH terms
- Animals, Cell Differentiation, Cell Transformation, Neoplastic, Disease Models, Animal, Epithelial Cells, Humans, Mice, Transgenic, Pancreatic Neoplasms, Pancreatitis, Signal Transduction, Survival Rate, Proto-Oncogene Proteins p21(ras), Mice, Hedgehog Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.